Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Prognostic Value of Tumor Tissue Up-regulated microRNAs in Clear Cell Renal Cell Carcinoma (ccRCC)

M. Pesta, I. Travnicek, V. Kulda, P. Ostasov, J. Windrichova, K. Houfkova, T. Knizkova, B. Bendova, O. Hes, M. Hora, O. Topolcan, J. Polivka

. 2024 ; 38 (4) : 1799-1805. [pub] -

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013335

BACKGROUND/AIM: The management of patients with clear cell renal cell carcinoma (ccRCC) includes prognosis assessment based on TNM classification and biochemical markers. This approach stratifies patients with advanced ccRCC into groups of favorable, intermediate, and poor prognosis. The aim of the study was to improve prognosis estimation using microRNAs involved in the pathogenesis of ccRCC. PATIENTS AND METHODS: The study was based on a histologically-verified set of matched ccRCC FFPE tissue samples (normal renal tissue, primary tumor, metastasis, n=20+20+20). The expression of 2,549 microRNAs was analyzed using the SurePrint G3 Human miRNA microarray kit (Agilent Technologies). Prognostic value of significantly deregulated microRNAs was further evaluated on microRNA expression and clinical data of 475 patients obtained from TCGA Kidney Clear Cell Carcinoma (KIRC) database. RESULTS: There were 13 up-regulated and 6 down-regulated microRNAs in tumor tissues compared to control tissues. Among them, survival analysis revealed those with prognostic significance. Patients with high expression of miR-21, miR-27a, miR-34a, miR-106b, miR-210, and miR-342 showed significantly unfavorable outcome. The opposite was observed for miR-30e, patients with low expression had significantly shorter survival. CONCLUSION: The inclusion of these microRNAs in a prognostic panel holds the potential to enhance stratification scoring systems, on which the treatment of ccRCC patients is based.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013335
003      
CZ-PrNML
005      
20240905134128.0
007      
ta
008      
240725s2024 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.13631 $2 doi
035    __
$a (PubMed)38936941
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
245    10
$a Prognostic Value of Tumor Tissue Up-regulated microRNAs in Clear Cell Renal Cell Carcinoma (ccRCC) / $c M. Pesta, I. Travnicek, V. Kulda, P. Ostasov, J. Windrichova, K. Houfkova, T. Knizkova, B. Bendova, O. Hes, M. Hora, O. Topolcan, J. Polivka
520    9_
$a BACKGROUND/AIM: The management of patients with clear cell renal cell carcinoma (ccRCC) includes prognosis assessment based on TNM classification and biochemical markers. This approach stratifies patients with advanced ccRCC into groups of favorable, intermediate, and poor prognosis. The aim of the study was to improve prognosis estimation using microRNAs involved in the pathogenesis of ccRCC. PATIENTS AND METHODS: The study was based on a histologically-verified set of matched ccRCC FFPE tissue samples (normal renal tissue, primary tumor, metastasis, n=20+20+20). The expression of 2,549 microRNAs was analyzed using the SurePrint G3 Human miRNA microarray kit (Agilent Technologies). Prognostic value of significantly deregulated microRNAs was further evaluated on microRNA expression and clinical data of 475 patients obtained from TCGA Kidney Clear Cell Carcinoma (KIRC) database. RESULTS: There were 13 up-regulated and 6 down-regulated microRNAs in tumor tissues compared to control tissues. Among them, survival analysis revealed those with prognostic significance. Patients with high expression of miR-21, miR-27a, miR-34a, miR-106b, miR-210, and miR-342 showed significantly unfavorable outcome. The opposite was observed for miR-30e, patients with low expression had significantly shorter survival. CONCLUSION: The inclusion of these microRNAs in a prognostic panel holds the potential to enhance stratification scoring systems, on which the treatment of ccRCC patients is based.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x genetika $x patologie $x mortalita $x metabolismus $7 D002292
650    12
$a mikro RNA $x genetika $7 D035683
650    _2
$a prognóza $7 D011379
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u nádorů $7 D015972
650    12
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a nádory ledvin $x genetika $x patologie $x mortalita $x metabolismus $7 D007680
650    12
$a stanovení celkové genové exprese $7 D020869
650    _2
$a staging nádorů $7 D009367
650    _2
$a upregulace $7 D015854
650    _2
$a dospělí $7 D000328
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a senioři nad 80 let $7 D000369
655    _2
$a časopisecké články $7 D016428
700    1_
$a Travnicek, Ivan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; vlastimil.kulda@lfp.cuni.cz
700    1_
$a Ostasov, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Windrichova, Jindra $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Houfkova, Katerina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Knizkova, Tereza $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Bendova, Barbora $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Hes, Ondrej $u Department of Pathology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Topolcan, Ondrej $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Polivka, Jiri $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 38, č. 4 (2024), s. 1799-1805
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38936941 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134122 $b ABA008
999    __
$a ok $b bmc $g 2143257 $s 1225201
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 4 $d 1799-1805 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20240725
Back

Find record

Citation metrics

Archiving options